The pemetrexed-containing treatments in the non-small cell lung cancer, is -low thymidylate synthase expression better than -high thymidylate synthase expression: a meta-analysisReportar como inadecuado




The pemetrexed-containing treatments in the non-small cell lung cancer, is -low thymidylate synthase expression better than -high thymidylate synthase expression: a meta-analysis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 14:205

Clinical oncology

Abstract

BackgroundThe predictive value of thymidylate synthase TS for clinical sensitivity to pemetrexed-containing chemotherapy in patients with non-small cell lung cancer NSCLC remains controversial. This meta-analysis is performed to provide an assessment of whether expression variations of TS are associated with objective response in patients with NSCLC treated with pemetrexed-containing chemotherapy.

MethodsAn electronic search was conducted using the databases MEDLINE, EMBASE and CNKI, from inception to June 10, 2013. A systemic review of the studies on the association between TS expression in NSCLC and objective response of pemetrexed-containing regimen was performed. Pooled odds ratios OR for the response rate were calculated using the software Revman 5.0.

ResultsThere were a total of 526 patients in the eight studies that met our criteria for evaluation. +-high expression of TS was found in 269 patients 51.1%, and -low expression for this gene was found in 257 48.9% patients. The objective response rate for pemetrexed-containing chemotherapy was significantly higher in patients with -low expression TS expression OR = 0.45; 95% CI, 0.29–0.70; p = 0.0004. Although patients with -low expression of TS have a longer median overall survival time and progression free survival time than those with +-high expression of TS, the difference was not statistically significant.

Conclusions−-low expression of TS was associated with higher objective response in NSCLC patients treated with pemetrexed-containing chemotherapy. TS may be a suitable marker of sensitivity to pemetrexed-based chemotherapy in patients with NSCLC.

KeywordsThymidylate synthase Pemetrexed Lung cancer Meta-analysis Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-14-205 contains supplementary material, which is available to authorized users.

Lei Wang, Rui Wang contributed equally to this work.

Download fulltext PDF



Autor: Lei Wang - Rui Wang - Yunjian Pan - Yihua Sun - Jie Zhang - Haiquan Chen

Fuente: https://link.springer.com/







Documentos relacionados